{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:48:48Z","timestamp":1791236928615,"version":"4.1.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T00:00:00Z","timestamp":1611014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although both angiotensin receptor blockers (ARBs) and dihydropyridine calcium channel blockers (CCBs) are all suitable for the initiation of antihypertensive treatment, studies investigating efficacy and safety between ARBs and CCBs are limited, and there is no previous study comparing their clinical outcomes during long-term follow-up periods in real world setting. We compared cardiovascular (CV) events between ARBs and CCBs in 464,948 hypertensive adults using the Korean National Health Insurance Service database during a 3-year follow-up. The patients with hypertension without heart failure, ischemic heart disease, cerebrovascular disease, or peripheral artery disease were enrolled. The CV events between only single prescription of CCBs and ARBs were finally compared. The primary endpoint for this study was the first occurrence of a major adverse CV events, defined as the composite of all-cause death, cardiac death, nonfatal myocardial infarction, or nonfatal stroke. ARB was significantly more administered in male and patients with higher income, diabetes mellitus, chronic kidney diseases, and higher Charlson comorbidity index. The primary endpoints occurred in 10,526 patients (5.2%) in the ARB group and in 19,363 patients (7.3%) in the CCB group (p\u2009&lt;\u20090.001) during a 3-year follow-up (HR 0.96, 95% CI 0.93\u20130.98). All the components of CV events including all-cause death, cardiac death, nonfatal myocardial infarction, and nonfatal stroke occurred more frequently in the CCB group. With multivariable models adjusting age, sex, income, diabetes, chronic kidney disease, and Charlson comorbidity index, the primary endpoints less frequently developed in the ARB group than in the CCB group (HR 0.957, 95% CI 0.933\u20130.983, p\u2009&lt;\u20090.001). After the propensity-score matching, baseline characteristics were similar and still showed significantly better primary endpoints in ARB group than CCB group (5.3% vs. 5.8%, p\u2009&lt;\u20090.001). In this nationwide population-based simple hypertension study, administration of ARBs showed superior protection against CV events than CCBs during a 3-year follow-up. Our results suggest that ARBs could be preferred over CCBs as the initial choice of antihypertensive treatment regardless of age in real-world practice.<\/jats:p>","DOI":"10.1038\/s41598-021-81373-7","type":"journal-article","created":{"date-parts":[[2021,1,19]],"date-time":"2021-01-19T11:09:05Z","timestamp":1611054545000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Clinical outcomes between calcium channel blockers and angiotensin receptor blockers in hypertensive patients without established cardiovascular diseases during a 3-year follow-up"],"prefix":"10.1038","volume":"11","author":[{"given":"Han Saem","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong\u2010Seok","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun-Jun","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Soo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin-Oh","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui Seung","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Ho","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soon Jun","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,19]]},"reference":[{"key":"81373_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad, D. et al. Blood pressure lowering for prevention of cardiovascular disease and death: A systematic review and meta-analysis. Lancet 387, 957\u2013967. https:\/\/doi.org\/10.1016\/S0140-6736(15)01225-8 (2016).","journal-title":"Lancet"},{"key":"81373_CR2","doi-asserted-by":"publisher","first-page":"1903","DOI":"10.1016\/s0140-6736(02)11911-8","volume":"360","author":"S Lewington","year":"2002","unstructured":"Lewington, S. et al. Age-specific relevance of usual blood pressure to vascular mortality: A meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 360, 1903\u20131913. https:\/\/doi.org\/10.1016\/s0140-6736(02)11911-8 (2002).","journal-title":"Lancet"},{"key":"81373_CR3","doi-asserted-by":"publisher","first-page":"e15","DOI":"10.1093\/ije\/dyv319","volume":"46","author":"J Lee","year":"2017","unstructured":"Lee, J., Lee, J. S., Park, S. H., Shin, S. A. & Kim, K. Cohort profile: The National Health Insurance Service-National Sample Cohort (NHIS-NSC), South Korea. Int. J. Epidemiol. 46, e15. https:\/\/doi.org\/10.1093\/ije\/dyv319 (2017).","journal-title":"Int. J. Epidemiol."},{"key":"81373_CR4","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1097\/HJH.0000000000002276","volume":"38","author":"F Spannella","year":"2020","unstructured":"Spannella, F. et al. Statin therapy is associated with better ambulatory blood pressure control: A propensity score analysis. J. Hypertens. 38, 546\u2013552. https:\/\/doi.org\/10.1097\/HJH.0000000000002276 (2020).","journal-title":"J. Hypertens."},{"key":"81373_CR5","doi-asserted-by":"publisher","first-page":"3021","DOI":"10.1093\/eurheartj\/ehy339","volume":"39","author":"B Williams","year":"2018","unstructured":"Williams, B. et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension. Eur. Heart J. 39, 3021\u20133104. https:\/\/doi.org\/10.1093\/eurheartj\/ehy339 (2018).","journal-title":"Eur. Heart J."},{"key":"81373_CR6","doi-asserted-by":"publisher","first-page":"e484","DOI":"10.1161\/CIR.0000000000000596","volume":"138","author":"PK Whelton","year":"2018","unstructured":"Whelton, P. K. et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. Circulation 138, e484\u2013e594. https:\/\/doi.org\/10.1161\/CIR.0000000000000596 (2018).","journal-title":"Circulation"},{"key":"81373_CR7","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1001\/jama.2013.284427","volume":"311","author":"PA James","year":"2014","unstructured":"James, P. A. et al. 2014 evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 311, 507\u2013520. https:\/\/doi.org\/10.1001\/jama.2013.284427 (2014).","journal-title":"JAMA"},{"key":"81373_CR8","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1111\/j.1751-7176.2010.00272.x","volume":"12","author":"KC Ferdinand","year":"2010","unstructured":"Ferdinand, K. C. Management of high blood pressure in African Americans and the 2010 ISHIB consensus statement: Meeting an unmet need. J. Clin. Hypertens. (Greenwich) 12, 237\u2013239. https:\/\/doi.org\/10.1111\/j.1751-7176.2010.00272.x (2010).","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"81373_CR9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1161\/HYPERTENSIONAHA.110.152892","volume":"56","author":"JM Flack","year":"2010","unstructured":"Flack, J. M. et al. Management of high blood pressure in Blacks: An update of the International Society on Hypertension in Blacks consensus statement. Hypertension 56, 780\u2013800. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.152892 (2010).","journal-title":"Hypertension"},{"key":"81373_CR10","unstructured":"National Guideline Centre (UK). Hypertension in adults: diagnosis and management. National Institute for Health and Care Excellence: Clinical Guidelines (National Institute for Health and Care Excellence (UK), London, 2019)."},{"key":"81373_CR11","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1097\/HJH.0000000000000614","volume":"33","author":"C Thomopoulos","year":"2015","unstructured":"Thomopoulos, C., Parati, G. & Zanchetti, A. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs\u2014Overview and meta-analyses. J. Hypertens. 33, 1321\u20131341. https:\/\/doi.org\/10.1097\/HJH.0000000000000614 (2015).","journal-title":"J. Hypertens."},{"key":"81373_CR12","first-page":"141","volume":"40","author":"KS Woo","year":"1995","unstructured":"Woo, K. S. & Nicholls, M. G. High prevalence of persistent cough with angiotensin converting enzyme inhibitors in Chinese. Br. J. Clin. Pharmacol. 40, 141\u2013144 (1995).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"81373_CR13","doi-asserted-by":"publisher","first-page":"4735876","DOI":"10.1155\/2019\/4735876","volume":"2019","author":"SH Kim","year":"2019","unstructured":"Kim, S. H. et al. Prescribing patterns of antihypertensives for treatment-naive patients in South Korea: From Korean NHISS claim data. Int. J. Hypertens. 2019, 4735876. https:\/\/doi.org\/10.1155\/2019\/4735876 (2019).","journal-title":"Int. J. Hypertens."},{"key":"81373_CR14","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1056\/NEJMoa011303","volume":"345","author":"EJ Lewis","year":"2001","unstructured":"Lewis, E. J. et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med. 345, 851\u2013860. https:\/\/doi.org\/10.1056\/NEJMoa011303 (2001).","journal-title":"N. Engl. J. Med."},{"key":"81373_CR15","doi-asserted-by":"publisher","first-page":"2022","DOI":"10.1016\/S0140-6736(04)16451-9","volume":"363","author":"S Julius","year":"2004","unstructured":"Julius, S. et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet 363, 2022\u20132031. https:\/\/doi.org\/10.1016\/S0140-6736(04)16451-9 (2004).","journal-title":"Lancet"},{"key":"81373_CR16","doi-asserted-by":"publisher","first-page":"1218","DOI":"10.1161\/01.STR.0000166048.35740.a9","volume":"36","author":"J Schrader","year":"2005","unstructured":"Schrader, J. et al. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention: Principal results of a prospective randomized controlled study (MOSES). Stroke 36, 1218\u20131226. https:\/\/doi.org\/10.1161\/01.STR.0000166048.35740.a9 (2005).","journal-title":"Stroke"},{"key":"81373_CR17","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1161\/HYPERTENSIONAHA.107.098475","volume":"51","author":"T Ogihara","year":"2008","unstructured":"Ogihara, T. et al. Effects of candesartan compared with amlodipine in hypertensive patients with high cardiovascular risks: Candesartan antihypertensive survival evaluation in Japan trial. Hypertension 51, 393\u2013398. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.098475 (2008).","journal-title":"Hypertension"},{"key":"81373_CR18","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/jch.12388","volume":"16","author":"L Wu","year":"2014","unstructured":"Wu, L., Deng, S. B. & She, Q. Calcium channel blocker compared with angiotensin receptor blocker for patients with hypertension: A meta-analysis of randomized controlled trials. J. Clin. Hypertens. (Greenwich) 16, 838\u2013845. https:\/\/doi.org\/10.1111\/jch.12388 (2014).","journal-title":"J. Clin. Hypertens. (Greenwich)"},{"key":"81373_CR19","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1291\/hypres.28.307","volume":"28","author":"H Suzuki","year":"2005","unstructured":"Suzuki, H., Kanno, Y. & Efficacy of Candesartan on Outcome in Saitama Trial Group. Effects of candesartan on cardiovascular outcomes in Japanese hypertensive patients. Hypertens. Res. 28, 307\u2013314. https:\/\/doi.org\/10.1291\/hypres.28.307 (2005).","journal-title":"Hypertens. Res."},{"key":"81373_CR20","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1136\/heartjnl-2016-310705","volume":"103","author":"L Potier","year":"2017","unstructured":"Potier, L. et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart 103, 1339\u20131346. https:\/\/doi.org\/10.1136\/heartjnl-2016-310705 (2017).","journal-title":"Heart"},{"key":"81373_CR21","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1161\/01.HYP.38.2.183","volume":"38","author":"HM Siragy","year":"2001","unstructured":"Siragy, H. M., de Gasparo, M., El-Kersh, M. & Carey, R. M. Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. Hypertension 38, 183\u2013186 (2001).","journal-title":"Hypertension"},{"key":"81373_CR22","doi-asserted-by":"publisher","first-page":"98S","DOI":"10.1016\/s0895-7061(01)02076-3","volume":"14","author":"RM Carey","year":"2001","unstructured":"Carey, R. M., Jin, X. H. & Siragy, H. M. Role of the angiotensin AT2 receptor in blood pressure regulation and therapeutic implications. Am. J. Hypertens. 14, 98S-102S. https:\/\/doi.org\/10.1016\/s0895-7061(01)02076-3 (2001).","journal-title":"Am. J. Hypertens."},{"key":"81373_CR23","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1586\/14779072.6.9.1195","volume":"6","author":"T Ogihara","year":"2008","unstructured":"Ogihara, T., Fujimoto, A., Nakao, K. & Saruta, T. ARB candesartan and CCB amlodipine in hypertensive patients: The CASE-J trial. Expert Rev. Cardiovasc. Ther. 6, 1195\u20131201. https:\/\/doi.org\/10.1586\/14779072.6.9.1195 (2008).","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"81373_CR24","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/s0002-9343(03)00158-x","volume":"115","author":"AU Klingbeil","year":"2003","unstructured":"Klingbeil, A. U., Schneider, M., Martus, P., Messerli, F. H. & Schmieder, R. E. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am. J. Med. 115, 41\u201346. https:\/\/doi.org\/10.1016\/s0002-9343(03)00158-x (2003).","journal-title":"Am. J. Med."},{"key":"81373_CR25","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0140-6736(07)60108-1","volume":"369","author":"WJ Elliott","year":"2007","unstructured":"Elliott, W. J. & Meyer, P. M. Incident diabetes in clinical trials of antihypertensive drugs: A network meta-analysis. Lancet 369, 201\u2013207. https:\/\/doi.org\/10.1016\/S0140-6736(07)60108-1 (2007).","journal-title":"Lancet"},{"key":"81373_CR26","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1001\/jama.292.19.2350","volume":"292","author":"RB Devereux","year":"2004","unstructured":"Devereux, R. B. et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JAMA 292, 2350\u20132356. https:\/\/doi.org\/10.1001\/jama.292.19.2350 (2004).","journal-title":"JAMA"},{"key":"81373_CR27","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1161\/HYPERTENSIONAHA.106.085654","volume":"50","author":"TA Aksnes","year":"2007","unstructured":"Aksnes, T. A. et al. Impact of new-onset diabetes mellitus on cardiac outcomes in the valsartan antihypertensive long-term use evaluation (VALUE) trial population. Hypertension 50, 467\u2013473. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.106.085654 (2007).","journal-title":"Hypertension"},{"key":"81373_CR28","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1291\/hypres.30.699","volume":"30","author":"F Kamezaki","year":"2007","unstructured":"Kamezaki, F. et al. Angiotensin receptor blocker improves coronary flow velocity reserve in hypertensive patients: Comparison with calcium channel blocker. Hypertens. Res. 30, 699\u2013706. https:\/\/doi.org\/10.1291\/hypres.30.699 (2007).","journal-title":"Hypertens. Res."},{"key":"81373_CR29","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1291\/hypres.31.841","volume":"31","author":"T Nakamura","year":"2008","unstructured":"Nakamura, T. et al. Comparison of renal and vascular protective effects between telmisartan and amlodipine in hypertensive patients with chronic kidney disease with mild renal insufficiency. Hypertens. Res. 31, 841\u2013850. https:\/\/doi.org\/10.1291\/hypres.31.841 (2008).","journal-title":"Hypertens. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81373-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81373-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,3]],"date-time":"2022-12-03T02:16:19Z","timestamp":1670033779000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-81373-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,19]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["81373"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-81373-7","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,19]]},"assertion":[{"value":"17 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1783"}}